In Caucasian volunteers and patients plasma sparfloxacin concentrations reached a peak of 1.2-1.5 mg/L between 3 and 6 h after a single 400 mg dose; T\ ranged from 16 to 22 h. The peak plasma concentration and the area under the plasma concentration-time curve exhibited dose-related increases but a slight decrease in the extent of absorption was observed following administration of doses above those recommended for clinical use. Renal clearance did not exceed 10% of the apparent plasma clearance. The urinary excretion of unchanged drug accounted for 9-10% of the dose administered and that of its glucuronide for 27-38% of the dose. The biliary excretion of the drug and its glucuronide accounted for about 1.5 and 11% of the dose administered, respectively. Following multiple-dose administration (200 mg daily after a loading dose of 400 mg on day 1), steady-state concentrations were achieved following the second dose. The peak plasma concentration was 1.4 mg/L and the trough concentration was 0.5 mg/L. The T\ was approximately 20 h. Studies in patients show that the pharmacokinetics of sparfloxacin were not influenced by age but severe renal failure markedly impaired elimination of the parent drug (the T\ was approximately doubled in patients with renal failure), and glucuronide, requiring adjustment of the dosage regimen. In patients with liver cirrhosis but no cholestasis, the pharmacokinetics of sparfloxacin were not markedly altered, although the urinary excretion of the glucuronide was about twice that observed in healthy volunteers. No modification of the usual dosage is recommended for these patients.
Introduction
Sparfloxacin is a new fluoroquinolone antibacterial agent with potent in-vitro and in-vivo activity, notably against pathogens responsible for respiratory tract infections and sexually transmitted diseases. Its pharmacokinetics in animals are characterised by a high degree of tissue distribution, with the exception of the central nervous system and adipose tissue, and a long serum half-life (T{). In all species tested, including man, the plasma protein binding (mainly to albumin) is weak (45-46%), and only one inactive metabolite, the acylglucuronide of sparfloxacin (Figure 1 ) has been found (Nakamura et al., 1990; Matsunaga et al., 1991) . No metabolism by oxidative mechanisms dependent on cytochrome P450 enzymes has been detected. Sparfloxacin and its glucuronide are eliminated by renal and non-renal processes including biliary excretion and probably transintestinal secretion, a pathway recently demonstrated for some (Sorgel el al., 1989; Griffiths, Hirst & Simmons, 1993) . In man, urinary excretion of unchanged drug and its glucuronide accounts for about 10 and 36% of the administered dose, respectively, whereas only unchanged sparfloxacin is recovered in faeces, accounting for 56% of the administered dose (Nakashima et al., 1991) . Studies performed in Japanese subjects reported the main pharmacokinetic characteristics of sparfloxacin in this population and assessed the wide distribution of the drug in a number of body fluids and tissues (Shimada, Nogita & Ishibashi, 1993) .
This review focuses on the pharmacokinetic studies performed in Caucasian subjects after various oral dosage regimens adminstered as a 100 mg tablet formulation. Sparfloxacin concentrations, unless otherwise specified, were determined using validated high pressure liquid chromatographic methods, with lower limits of quantification ranging from 15 to 50/zg/L for plasma and from 0.2 to 0.9 mg/L for urine. The concentrations of sparfloxacin were also determined after alkaline hydrolysis of the glucuronide, and results were expressed as 'total sparfloxacin' or as 'sparfloxacin glucuronide' (calculated as total minus unchanged sparfloxacin and expressed in sparfloxacin equivalents). Pharmacokinetic parameters were determined using noncompartmental analysis (Gibaldi & Perrier, 1982) .
Pharmacokinetic characteristics of sparfloxacin

Pharmacokinetics after single dose administration
Most of the single-dose pharmacokinetic studies performed in healthy volunteers evaluated a 400 mg dose of sparfloxacin, which is the loading dose of the recommended therapeutic regimen (400 mg on day 1, then 200 mg once daily). The results are summarised in Table I . As no iv formulation was available, the absolute bioavailability of sparfloxacin was not determined in man. Therefore, the values calculated for the apparent volume of distribution of the drug after oral administration (4-6 L/kg) which suggest a large distribution, possibly larger than those of other quinolone antibiotics, will not be reported here.
The absorption of sparfloxacin begins soon after administration, with mean 1-h concentrations generally about 0.9-1 mg/L, but is a relatively long process with the peak concentration usually not observed before 3 to 5 h post-administration. The mean peak concentration (C B » 1 ) ranged between 1.2 and 1.6 mg/L. The rate of absorption was characterised by patient intervariability, as indicated by the wide range of values observed for T wmx : 0.5-10 h. As a consequence, the G»« value tended to decrease when Taa increased.
The reasons for this variability in the rate of absorption are unclear but may be related to a long absorption process (absorption from the duodenum to the colon has Table I . Pharmacokinetic parameters of sparfloxacin (mean ± S.D.) following a single oral 400 mg dose to healthy volunteers Number or been demonstrated in animals (Matsunaga et al., 1991) , as well as to the concomitant existence of active processes in intestinal absorption and secretion of sparfloxacin. Moreover, the influence of the dosage form on drug absorption has not been investigated. Since the biliary excretion of sparfloxacin and of its glucuronide is relatively minor (about 13% of dose, see below), it is probable that enterohepatic circulation does not play an important role in drug reabsorption. The T m of sparfloxacin is long (16-20h) and has been quite similar in different studies. The renal clearance is low (<25mL/min) and accounts for less than 15% of apparent plasma clearance, indicating that non-renal processes are the major routes of drug elimination.
Data gathered from four studies in which all urine was collected for at least 4 days after administration of a single 400 mg dose, indicate that the urinary excretion of unchanged sparfloxacin and its glucuronide accounts for 9-10% and 18-28% of dose, respectively (Table II) . Therefore, the urinary excretion of total sparfloxacin represents 28-38% of the administered dose.
The plasma concentrations of the glucuronide metabolite were determined in two studies in volunteers given a single 400 mg dose (Wittke et al., 1992; Fillastre et al., 1994) . C was 0.35 ± 0.13 mg/L (at T^ 5 h) and 0.91 ± 0.32 mg/L (at T^ 2 h), whereas AUC was 6.84 ± 4.28 and 15.10 ± 4.79 mg.h/L, respectively. These plasma concentrations accounted for 22% and 45% of parent drug plasma concentrations, as compared with values of 30-40% reported for Japanese volunteers (Nakashima et al., 1991) .
The dose-dependency of the pharmacokinetics of sparfloxacin has been studied in a cross-over study after single-dose administration of 200, 400, 600 and 800 mg orally to 12 healthy volunteers . The data indicate a slight decrease of sparfloxacin bioavailability with increasing dose since the increases in C MJ and AUC were less than the dosage increase (Table III) . The AUC was approximately 87 to 88% of the expected area when the dose was doubled. As a result, the apparent plasma clearance tends to increase with increasing dose. The T m of sparfloxacin was constant over the dose range studied, with a mean value of about 20 h. The urinary excretion of unchanged sparfloxacin and its glucuronide also tended to decrease with increasing dose, since the 'total drug' excreted decreased from about 32.6 to 25.4% of administered dose between 200 and 800 mg. The renal clearance of drug was constant at approximately 20 mL/min, as was the metabolic ratio of 2.1-2.3, calculated as glucuronide/parent drug urinary excretion. The data indicate that the slight decrease in 35.6 ± 6.9 28.0 ± 8.5 30.87 ± 7.84 37.6 ± 7.55 Thebault et al., (1990 ) Mignot et al., (1990 Montay et al., (1994) Kinzig et al., (1992) 25.44 ± 6.62 excreted in urine for unchanged or total (unchanged plus glucuronic acid-conjugated) drug; Metabolic ratio = total recovery; for other definitions see Table I . 
sparfloxacin bioavailability is related to a decrease in drug absorption when dosage increases. This decrease may be because absorption is limited by the low solubility of sparfloxacin in the gastrointestinal contents (sparfloxacin solubility in water is <0.04mg/L at pH 1.0 and <0.2g/L at pH 7.4) and/or involves a saturable active process, the carrier-mediated transport system of di-and tri-peptides, which has been demonstrated in rats (Yamaguchi el al., 1991) . This slight decrease in sparfloxacin bioavailability is assumed to be of no therapeutic consequence because it occurs only for doses above those recommended for clinical use. Moreover, the bioavailability data obtained after repeated administration of sparfloxacin did not give evidence for a decrease of bioavailability with increasing dose, suggesting that these phenomena is of very limited significance.
Pharmacokinetics after repealed dose administration
As part of a tolerance study, the pharmacokinetics of sparfloxacin were determined in four parallel groups of eight subjects receiving 200, 400, 600 and 800 mg on day 1, and then 100, 200, 300 and 400 mg once daily for 9 days (Vital-Durand, D. & Sibille, M., unpublished data). These four doses were evaluated before clinical trials were performed in patients, taking into account the pharmacokinetic characteristics of sparfloxacin, notably its long T, n allowing once daily administration. The results are presented in Table IV determined from the single dose studies. The accumulation ratio AUC0-24 day 10/AUCo-M day 1 was close to 2: its mean value was 1.75, 1.65, 2.05 and 2.18 for the different doses tested. This value is close to the theoretical value, calculated from 1/(1 -e -/?T) where P = \n2IT hl and x is dosage interval, which is about 1.8-1.9 for a T ia of 20-22 h. Therefore, the sparfloxacin pharmacokinetic data obtained after a 10-day treatment are not time-dependent but are consistent with single dose data.
The Cm« and AUC values on day 10 did not differ between doses, when normalised. The regression lines between these parameters and the administered dose are: Following the 400/200 mg dosage regimen, the sparfloxacin C mn was above the MIC of susceptible strains, including Streptococcus pneumoniae (MIC90 0.25 mg/L). In view of these favourable plasma pharmacokinetic properties of sparfloxacin, in conjunction with its good tissue diffusion, a 400 mg loading dose achieves the 0.5 mg/L plasma threshold at 24 h and steady-state concentrations are rapidly attained.
Fluid and tissue distribution
Numerous studies in Japanese subjects investigated the distribution of sparfloxacin in human tissues, fluids or secretions, and confirmed the high penetration of the drug in the commonly infected sites (see Shimada et al., 1993) A blister diffusion study using bioassay was performed in six Caucasian volunteers receiving a 400 mg single dose of drug (Johnson et al., 1992) . Good penetration of sparfloxacin into inflammatory fluid was observed; the fluid/plasma ratio was close to 1.0 from 6 to 26 h post-dose and was about 1.5 at 56 h. The extent of penetration, as measured by the blister fluid/plasma ratio was 117 ±21%. The elimination of sparfloxacin from the fluid paralleled that from plasma, as indicated by similar T m values (19.7 ± 7.6 and 17.6 ±2.0 h, respectively). The excellent distribution of sparfloxacin into the human respiratory tract is specifically addressed in another article of this journal supplement (Wise & Honeybourne, 1996) .
Biliary excretion
The biliary excretion of sparfloxacin was determined in 12 patients (five males; seven females) undergoing cholecystectomy who received a single oral 400 mg dose (Wittke et al., 1992) . The 0-72 h biliary excretion of free drug and of its glucuronide accounted for 1.51 ±1.00 and 11.50 ±6.85% (range: 4.6-27.1%) of the administered dose, respectively. Although incomplete collection of bile in these patients cannot be excluded and may explain the variability observed, the biliary excretion of sparfloxacin appears to be only moderate, thus limiting the possible role of enterohepatic circulation in drug reabsorption.
Phannacokinetics in the elderly and in patients with renal failure or liver cirrhosis
Tolerance and pharmacokinetic studies of sparfloxacin have been performed in elderly people, and in patients in severe renal failure or with cirrhosis of the liver.
Pharmacokinetics in elderly people
In the first double-blind, placebo controlled study designed to assess the tolerance of the drug after singJe-dose administration, eight healthy elderly subjects per group (four males, four females) aged 75 ± 3.6 years received three oral doses of 100, 200, 400 or 600 mg of sparfloxacin or a placebo (2 subject per group), and preliminary pharmacokinetics were determined (Jonkman J. H. G. & Zuiderwijk, P. B. M., unpublished data). The results, presented in Table V , indicate that C^ and AUC increased proportionally with dose, and that the pharmacokinetics of sparfloxacin in elderly people with normal hepatic and renal functions are not different from those in young subjects. Indeed, similar values were found for Tw and plasma and renal clearance, as well as for urinary excretion.
Following on from the single-dose study, the pharmacokinetics and tolerance of sparfloxacin after repeated doses were evaluated in ten elderly people (five males, five females) aged 69.5 ± 3.4 years who received 400 mg on day 1, then 200 mg once daily for 6 days (Montay et al., 1991) . The pharmacokinetic data, presented in Table VI and Figure 3 , were compared between male and female subjects and were also compared with the data obtained in young volunteers given the same therapeutic dosage regimen (see Table III ). Although the absolute sparfloxacin concentrations tended to be higher in female than in male subjects, there were no significant sex-related differences for Câ nd AUC values corrected for subject body weight or for T l/2 and clearance values. There were no significant differences between elderly and young people for any of the pharmacokinetic parameters. Therefore, there is no pharmacokinetic rationale for modifying the recommended sparfloxacin dosage regimen according to the age of the patient.
Pharmacokinetics in patients with renal failure
The pharmacokinetics of a single 400 mg dose of sparfloxacin were determined in 14 patients with severe chronic renal failure: seven with creatinine clearance between 10 and 30 mL/min and seven with creatinine clearance < 10 mL/min (Fillastre et al., 1994) . There were no significant differences between the two groups of patients for any of the Table V . Pharmacokinetic parameters (mean ± S.D) of sparfloxacin in elderly people (n = 6 per group) following single dose administration For definitions see Table I . pharmacokinetic parameters of sparfloxacin (Table VII) , although lower renal and non-renal clearances were observed in patients with creatinine clearance < lOmL/min. Compared with data in young volunteers (Table III) , the T m of sparfloxacin was significantly higher (approximately double) in patients with renal failure. The renal clearance and urinary excretion were significantly lower in these patients compared with young volunteers (Table III) , and there was a significant relationship (r 2 = 0.43, P = 0.011) between renal clearance of sparfloxacin and creatinine clearance. Non-renal clearance was moderately lower (by about 30%) in patients with the highest renal impairment but the difference was not statistically significant. All the pharmacokinetic parameters of sparfloxacin glucuronide, except T,^, were modified in the patients; it is noteworthy that the AUC was about four to ten times greater than in healthy subjects. There was a significant positive relationship between sparfloxacin glucuronide renal clearance and creatinine clearance of the patients (r 2 = 0.68, P = 0.002).
The results of this study indicate that the elimination of sparfloxacin is markedly impaired and sparfloxacin glucuronide accumulates in patients with severe renal failure. However, despite the positive relationship between creatinine clearance and glucuronide renal clearance no relationship between plasma sparfloxacin or glucuronide concentrations and creatinine clearance of the patients was observed, probably because the drug and its metabolite are cleared by both renal and non-renal processes. Nevertheless, a modification of the therapeutic dosage regimen is required in these patients. Taking into account these results, a 400 mg loading dose on day 1, followed by a 200 mg daily dose every second day, has been proposed. It has been hypothesised that accumulation of sparfloxacin glucuronide and its hydrolysis to sparfloxacin may explain the increase in T ul of the parent drug seen in patients with renal failure.
Pharmacokinetics in patients with liver cirrhosis
The pharmacokinetics of a single 400 mg dose of sparfloxacin were determined in 12 patients (seven males, five females, aged 53 ± 10 years, weighing 69 ± 15 kg) with Table I.   2   Table VII . Pharmacokinetic parameters (mean ± S.D.) of sparfloxacin after oral administration of a single 400 mg dose, in patients with renal failure Group of patients
Creatinine clearance 10-30mL/min (n = 7) 
Creatinine clearance histologically proven cirrhosis but without cbolestasis and ascites (Mugnier et al., 1994) . The results are presented in Table IX . Sparfloxacin pharmacokinetic parameters in these patients were similar to those in healthy volunteers (see Table III ), except for urinary excretion of conjugated drug which was higher in patients. Moreover, there was no significant relationship between drug plasma clearance and the Child & Pugh index of patients for hepatic insufficiency (Child, 1964; Pugh et al., 1973) .
The pharmacokinetics of a single 200 mg dose were also determined in four patients with cirrhosis and cholestasis and of a 400 mg dose in five patients with cirrhosis and ascites (Mugnier et al., 1994) . Sparfloxacin pharmacokinetic parameters in these two groups of patients was also similar to those of healthy volunteers, except for urinary excretion of conjugated drug which was also higher in patients. It is likely that sparfloxacin plasma kinetics are not markedly modified in cirrhotic patients. Therefore, no change in drug dosage regimen based on drug kinetics appears to be justified.
The plasma concentrations of the glucuronide were highly variable (CV was about 82%) and represented about 73% of unchanged drug concentration (mean value of AUC ratios), which is higher than in healthy subjects (20-45%). The apparent T\p of the glucuronide was close to that of unchanged drug, as previously observed in healthy subjects. The urinary excretion of the glucuronide was notably higher, since it represented about 45% of the administered dose, about twice that observed in volunteers. This suggests that an increase in renal excretion of the glucuronide may compensate for the decrease in non-renal excretion.
Conclusion
The pharmacokinetic profile of sparfloxacin has been characterised in Caucasian volunteers and patients. Absorption begins soon after administration, but the time to achieve peak plasma concentration generally occurs 3-5 h after drug intake, with a wide variability (0.5-10 h). This may be related to different processes-absorption, secretion and reabsorption-occurring through most of the intestinal tract. It is unlikely that enterohepatic circulation is of major importance in the reabsorption process. The relationship between plasma concentrations and dosage is linear, although a slight decrease in the extent of absorption is apparent after administration of doses exceeding those recommended for therapeutic use.
The long T m (18-22 h) of sparfloxacin makes it suitable for once daily dosing. After administration of a single loading dose of twice the maintenance dosage, steady-state concentrations are achieved following the second dose. Sparfloxacin is eliminated primarily by non-renal processes; renal clearance accounts for only about 10% of plasma clearance. Sparfloxacin clearance is not time-dependent. The glucuronide metabolite is excreted renally and into bile. The role of intestinal secretion in sparfloxacin elimination has not yet been studied in man.
The pharmacokinetics of sparfloxacin are not influenced by old age, but severe renal failure markedly impairs the elimination of both parent drug and glucuronide, requiring an adjustment of the dosage regimen. Cirrhosis does not dramatically affect sparfloxacin plasma pharmacokinetics; however an increase in renal excretion of the glucuronide is observed (data on file; Rhone-Poulenc Rorer). Further evaluation of sparfloxacin in phase III trials, using population pharmacokinetics, confirmed that the patient age is not a covariate that significantly affects sparfloxacin pharmacokinetics, whereas renal function status is. 
